A lot of what gets sold online in 2026 as “compounded GLP-1” isn’t coming from a U.S.-licensed pharmacy at all. It’s coming from grey-market channels — vendors operating outside the prescription and pharmacy-licensure system entirely — and the FDA has been actively targeting this category through warning letters and import restrictions for more than a year now.
The problem for patients is that both categories can look nearly identical on a landing page. A well-designed website, a checkout flow, a product photo of a labeled vial — none of that tells you whether what’s behind it is a state-licensed compounding pharmacy filling a valid prescription, or an unregulated seller shipping a product with no clinician involved at any point. Compounded medications are not FDA-approved products, full stop — that's true whether they come from a properly licensed pharmacy or a grey-market source. But the regulatory gap between those two sources is enormous, and it's the gap this guide is built to help you see.
Below is the framework: what licensed compounding actually is, what grey-market GLP-1 actually is, why the FDA treats the difference as a safety issue rather than a technicality, and a practical checklist you can use before you order anything.
What “Licensed Compounding” Actually Means (503A vs 503B)
Compounding is the practice of a pharmacy preparing a customized medication for a patient, typically when a commercially manufactured product doesn't fit that patient's specific clinical situation. The FDA regulates two distinct categories of legal compounding, and understanding the difference is the foundation of this entire topic. The agency's policy update on compounders as the national GLP-1 supply stabilized lays out the current framework in detail.
503A pharmacies are state-licensed pharmacies that compound patient-specific prescriptions. A 503A pharmacy prepares a medication only after receiving a valid prescription from a licensed clinician for a named, individual patient. These pharmacies are licensed and inspected at the state level through their state board of pharmacy.
503B outsourcing facilities are a separate category: federally registered facilities that can compound in larger batches, under a higher tier of FDA oversight, and can supply to clinics and practices rather than only to a single named patient at a time.
Both categories are legally distinct from the grey market, and both share one non-negotiable requirement: a valid prescription from a U.S.-licensed clinician tied to a real patient. Neither 503A nor 503B compounding means a product is FDA-approved — compounded drugs, by definition, have not gone through the FDA's premarket approval process. What licensure means is that the pharmacy is operating inside a known, inspectable regulatory system, rather than outside of it.
The FDA's compounding framework also changed materially in 2025. Semaglutide came off the 503A drug shortage list on April 22, 2025, and off the 503B list on May 22, 2025. Tirzepatide came off the 503A list on February 18, 2025, and off the 503B list on March 19, 2025, according to the FDA's compounder policy update. Once a drug is off the shortage list, mass compounding of essentially copycat versions is no longer permissible under the shortage exemption — compounding for an individual patient's documented clinical need under 503A can still occur under narrower conditions. This shift is part of why the market has fragmented, and part of why grey-market sourcing has become more visible.
What “Grey-Market GLP-1” Actually Means
Grey-market GLP-1 refers to semaglutide, tirzepatide, or related compounds sold outside the licensed pharmacy and prescription system altogether. It is not the same category as licensed 503A or 503B compounding, even when a seller uses similar language on a website.
Common characteristics of grey-market GLP-1 sourcing include:
- No prescription requirement. Product ships directly to the buyer without any clinician reviewing the order.
- No licensed pharmacy involved. There is no compounding pharmacy of record, no pharmacist verifying the preparation, and nothing to look up on a state board of pharmacy website.
- Foreign-sourced active pharmaceutical ingredient (API). The raw material frequently comes from manufacturers that are not on the FDA's approved supplier list for these ingredients.
- Mislabeling as a workaround. Vials are often labeled “for research use only” or “not for human consumption” — language that attempts to sidestep drug regulations while the product is being marketed and used as an injectable weight-loss drug.
In September 2025, the FDA issued Import Alert 66-80, which restricts the import of GLP-1 active pharmaceutical ingredients from foreign manufacturers that are not on an approved “Green List.” This alert was specifically aimed at cutting off the foreign-API pipeline that feeds a large share of the grey market. If a seller can't speak to where its API comes from, or whether that manufacturer appears on the FDA's approved list, that's a sourcing question worth taking seriously — not a technicality.
Why the Distinction Matters (FDA's Position)
The FDA has been direct about the baseline risk of compounded drugs generally. In its alert on dosing errors associated with compounded semaglutide and tirzepatide products, the agency states that compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, quality, or effectiveness. That statement applies to all compounded medication — including compounding done correctly, by a licensed pharmacy, under a valid prescription.
Grey-market product carries a materially higher layer of risk on top of that baseline, because it strips away the safeguards that licensed compounding still provides: a pharmacist reviewing the preparation, a clinician confirming the prescription is appropriate for that patient, a state board of pharmacy that can inspect the facility, and a manufacturer of record for the API. The FDA's own overview of its concerns with unapproved GLP-1 drugs used for weight loss is explicit that products from unregistered or unlicensed sources have been found with incorrect ingredients, contamination, or significantly different potency than labeled — problems that licensed-pharmacy oversight exists specifically to catch.
The core distinction, in one sentence: licensed compounding is not FDA-approved, but it operates inside a known, inspectable regulatory system with a pharmacist and a prescription in the loop. Grey-market product operates outside that system entirely.
How to Identify a Licensed Compounding Pharmacy
This is the practical part. Six checkpoints that separate a licensed compounding pharmacy from everything else, in order of how quickly you can check them.
- Requires a valid prescription from a U.S.-licensed clinician. No prescription review, no legitimate compounded product. This is the single fastest filter.
- Names the compounding pharmacy on the label. A licensed pharmacy has nothing to hide and identifies itself. If the label or paperwork never names an actual pharmacy, there is no pharmacy of record to verify.
- Holds a current state-board license that you can verify. Every state board of pharmacy maintains a public license lookup. A named pharmacy should show up, in good standing, in the state where it's licensed.
- Operates as either a 503A or 503B facility — and you can tell which. 503A pharmacies compound patient-specific prescriptions; 503B outsourcing facilities are FDA-registered and compound at larger scale. A legitimate provider can tell you which category applies and back it up.
- Describes its compounded product accurately, without brand-equivalence claims. A licensed pharmacy describes its compounded product accurately as a compounded preparation and does not claim FDA approval or equivalence to any brand-name drug.
- Does not import API from unverified foreign sources. A pharmacy operating in good standing sources its active pharmaceutical ingredient from manufacturers that meet FDA sourcing standards, not from unregistered overseas suppliers.
Red Flags of Grey-Market Vendors
The FDA's warning-letter record over the past year points to a consistent pattern of grey-market red flags. None of these require special expertise to spot — they're visible on the seller's own website, before you ever place an order.
- “For research use only” or similar disclaimers on a product being marketed and sold for injection into a human body.
- No prescription requirement — checkout proceeds with no clinician review of any kind.
- No clinician review at any point in the ordering process, even a cursory one.
- No pharmacy identification on the label or in the order paperwork — nothing to verify against a state board of pharmacy.
- Pricing dramatically below the licensed compounding market rate, with no clear explanation for the gap.
- Foreign shipping origins for a product being sold as a U.S. pharmacy preparation.
These are the same patterns the FDA has referenced across its warning-letter enforcement framework, tracked on the agency's compounding inspections, recalls, and other actions index. The goal here isn't to name and shame individual sellers — it's to recognize the pattern regardless of which vendor happens to be running it.
What the FDA Has Been Doing (2025–2026 Enforcement Timeline)
The FDA has sent at least three waves of warning letters targeting misleading or unapproved GLP-1 claims since late 2025, part of a broader pattern of multiple 2025–2026 FDA enforcement actions in this space. A brief factual timeline:
The consistent thread across all three waves is misleading marketing — primarily claims of FDA approval or brand equivalence that the products don't have, and sourcing practices that fall outside the licensed compounding system. The full FDA compounding-actions index is the best way to check on any specific enforcement history.
7 Questions to Ask Before You Order Compounded GLP-1
Use this checklist before you order from any provider — telehealth platform, med spa, or direct-to-consumer website.
- Is there a real prescription review by a U.S.-licensed clinician? Not a form you fill out that auto-approves — an actual clinical review tied to your history.
- What compounding pharmacy is on the label — and can you verify their state license? Get the pharmacy name and check it against the relevant state board of pharmacy lookup.
- Is the product labeled “for research use only” or anything similar? That language on a product being sold for human use is a serious red flag, not boilerplate.
- Does the seller claim their product is “FDA-approved” or equivalent to any brand-name GLP-1? The FDA has issued warning letters over exactly this kind of claim.
- Where is the API sourced — is the manufacturer on the FDA's Green List? A legitimate pharmacy should be able to answer this without hesitation.
- Is there a licensed U.S. address for the pharmacy and the clinical practice? Both should be verifiable, not a P.O. box or an address that doesn't match the state license.
- What's the pharmacy's inspection history? The FDA's compounding inspections, recalls, and other actions page is a starting point for checking whether a facility has any documented history worth knowing about.
If you can't get a straight answer to any of these seven questions within a normal conversation, treat that as the answer.
How SkinnyVIP Handles This
SkinnyVIP is a physician-led telehealth practice. Prescriptions are written by U.S.-licensed clinicians for individual patients, based on an actual clinical review. Compounded semaglutide and tirzepatide are prepared by licensed compounding pharmacies under physician supervision, and the pharmacy is identified on your prescription so it can be verified. Compounded medications are not FDA-approved products. Individual results vary.
If you want to see how the clinical and prescribing process actually works, how SkinnyVIP's compounded tirzepatide program works walks through it in detail, and the flat, no-membership pricing page lays out the full cost with nothing hidden in a separate membership fee. For a broader look at how compounded GLP-1 pricing compares across telehealth providers, see the full 2026 compounded GLP-1 pricing comparison.
SkinnyVIP is not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®).